Int J Clin Pharm Th
-
Int J Clin Pharm Th · Dec 2016
Corrective effect of norepinephrine on hypotension induced by dexmedetomidine in critically ill patients.
To evaluate the corrective effect of norepinephrine on hypotension induced by dexmedetomidine through monitoring sedation status, hemodynamics as well as oxygen metabolism. ⋯ Dexmedetomidine plays an important role in ICU patients due to its pharmacological ability of sedation and analgesia. In our study, dexmedetomidine was successfully applied to ensure goal-directed sedation therapy (GDST). Norepinephrine can correct hypotension and bradycardia induced by intravenous dexmedetomidine. According to the hemodynamic indexes and oxygen metabolism indexes, the application of dexmedetomidine or the combination of dexmedetomidine with norepinephrine are both safe and appropriate to maintain the sedation status and hemodynamic situation in ICU patients. .
-
Int J Clin Pharm Th · Oct 1998
Randomized Controlled Trial Clinical TrialProspective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
The efficacy and safety of amikacin administered once-daily versus twice-daily was evaluated in adult patients with systemic infections. Patients over 23 years of age with suspected or documented systemic infections were randomly divided into two groups: one group received amikacin intravenously 15 mg/kg once-daily, and the other group received amikacin 15 mg/kg divided into 2 doses. The efficacy of both dosage regimens was very good with a satisfactory clinical response in 90.2% and 89%, respectively. ⋯ No significant differences between the regimens with regard to hearing loss or prodromal signs of ototoxicity. We concluded that amikacin administered once-daily appears to be as effective and safe as the twice-daily dosing. However, the once-daily administration is more convenient and less costly.
-
Int J Clin Pharm Th · Dec 1998
Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
Levosimendan is a new calcium sensitizer, acting calcium-dependently on cardiac troponin C. In the present study pharmacokinetic-pharmacodynamic interrelations of levosimendan were assessed. ⋯ In conclusion, the pharmacokinetic-dynamic behavior of the inotropy index QS2i indicates an equilibration delay of levosimendan, which most probably reflects the time the drug requires to distribute from plasma to its cardiac site of action. The deviant kinetic-dynamic profile of the oral slow-release formulation suggests a different absorption pattern of levosimendan from this formulation.